Inflammation as well as angiogenesis may participate in the pathophysiology of brain radiation necrosis

Journal of Radiation Research

Volumn 55, Issue 4, 2014, Pages 803-811

  Yoritsune, Erina ^a   Furuse, Motomasa ^a   Kuwabara, Hiroko ^a   Miyata, Tomo ^a   Nonoguchi, Naosuke ^a   Kawabata, Shinji ^a   Hayasaki, Hana ^a   Kuroiwa, Toshihiko ^a   Ono, Koji ^b   Shibayama, Yuro ^a   Miyatake, Shin Ichi ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

brain radiation necrosis; CXCL12 CXCR4 chemokine axis; inflammation; microglia; pro inflammatory cytokine

Indexed keywords

CELLS; CYTOLOGY; PATHOLOGY; THIN WALLED STRUCTURES;

ANGIOGENESIS; BRAIN RADIATION NECROSE; CHEMOKINES; CXCL12/CXCR4 CHEMOKINE AXIS; HAEMATOXYLIN; HIF-1Α; MICROGLIA; PATHOPHYSIOLOGY; PROINFLAMMATORY CYTOKINES; RADIATION NECROSIS;

BRAIN;

CHEMOKINE; CHEMOKINE RECEPTOR;

ADULT; ADVERSE EFFECTS; AGED; BRAIN INJURIES; BRAIN NEOPLASMS; FEMALE; HUMAN; INFLAMMATION; MALE; METABOLISM; MIDDLE AGED; NECROSIS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PATHOPHYSIOLOGY; RADIATION INJURIES;

ADULT; AGED; BRAIN INJURIES; BRAIN NEOPLASMS; CHEMOKINES; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NECROSIS; NEOVASCULARIZATION, PATHOLOGIC; RADIATION INJURIES; RADIOTHERAPY; RECEPTORS, CHEMOKINE;

EID: 84901275157     PISSN: 04493060     EISSN: 13499157     Source Type: Journal    
DOI: 10.1093/jrr/rru017     Document Type: Article

References (36)

1. Furuse M, Kawabata S, Kuroiwa T et al. Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases. J Neurooncol 2011;102:471-5.
2. Gonzalez J, Kumar AJ, Conrad CA et al. Effect of bevacizu-mab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 2007;67:323-6.
3. Levin VA, Bidaut L, Hou P et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2011;79:1487-95.
4. Nonoguchi N, Miyatake S, Fukumoto M et al. The distribution of vascular endothelial growth factor-producing cells in clinical radiation necrosis of the brain: pathological consideration of their potential roles. J Neurooncol 2011;105:423-31.
5. Miyatake S, Kuroiwa T, Kajimoto Y et al. Fluorescence of non-neoplastic, magnetic resonance imaging-enhancing tissue by 5-aminolevulinic acid: case report. Neurosurgery 2007;61: E1101-3; discussion E1103-4.
6. Kryczek I, Wei S, Keller E et al. Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol 2007;292:C987-95.
7. Liang Z, Brooks J, Willard M et al. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun 2007;359:716-22.
8. Yoshii Y. Pathological review of late cerebral radionecrosis. Brain Tumor Pathol 2008;25:51-8.
9. Kawabata S, Miyatake S, Kuroiwa T et al. Boron neutron capture therapy for newly diagnosed glioblastoma. J Radiat Res 2009;50:51-60.
10. Miyatake S, Kawabata S, Kajimoto Y et al. Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages. J Neurosurg 2005;103:1000-9.
11. Miyatake S, Kawabata S, Nonoguchi N et al. Pseudo-progression in boron neutron capture therapy for malignant gliomas and meningiomas. Neuro-Oncology 2009;11:430-6.
12. Miyatake S, Kawabata S, Yokoyama K et al. Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas. J Neurooncol 2009;91:199-206.
13. Miyatake S, Tamura Y, Kawabata S et al. Boron neutron capture therapy for malignant tumors related to meningiomas. Neurosurgery 2007;61:82-90; discussion 90-1.
14. Ruben JD, Dally M, Bailey M et al. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 2006;65:499-508.
15. de Wit MC, de Bruin HG, Eijkenboom W et al. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 2004;63:535-7.
16. Maxwell PH, Wiesener MS, Chang GW et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5.
17. Kureshi SA, Hofman FM, Schneider JH et al. Cytokine expression in radiation-induced delayed cerebral injury. Neurosurgery 1994;35:822-9; discussion 829-30.
18. Ansari R, Gaber MW, Wang B et al. Anti-TNFA (TNF-alpha) treatment abrogates radiation-induced changes in vascular density and tissue oxygenation. Radiat Res 2007;167:80-6.
19. Mantych GJ, James DE, Devaskar SU. Jejunal/kidney glucose transporter isoform (Glut-5) is expressed in the human blood-brain barrier. Endocrinology 1993;132:35-40.
20. Siu A, Wind J, Iorgulescue J et al. Radiation necrosis following treatment of high grade glioma-a review of the literature and current understanding. Acta Neurochir 2012;154:191-201.
21. Wilson CM, Gaber MW, Sabek OM et al. Radiation-induced astrogliosis and blood-brain barrier damage can be abrogated using anti-TNF treatment. Int J Radiat Oncol Biol Phys 2009;74:934-41.
22. Nakae S, Saijo S, Horai R et al. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA 2003;100:5986-90.
23. McCandless EE, Wang Q, Woerner BM et al. CXCL12 limits inflammation by localizing mononuclear infiltrates to the perivascular space during experimental autoimmune encephalo-myelitis. J Immunol 2006;177:8053-64.
24. Cristillo AD, Highbarger HC, Dewar RL et al. Up-regulation of HIV coreceptor CXCR4 expression in human T lymphocytes is mediated in part by a cAMP-responsive element. FASEB J 2002;16:354-64.
25. Forster R, Kremmer E, Schubel A et al. Intracellular and surface expression of the HIV-1 coreceptor CXCR4/fusin on various leukocyte subsets: rapid internalization and recycling upon activation. J Immunol 1998;160:1522-31.
26. Burant CF, Takeda J, Brot-Laroche E et al. Fructose transporter in human spermatozoa and small intestine is GLUT5. J Biol Chem 1992;267:14523-6.
27. Gould GW, Holman GD. The glucose transporter family: structure, function and tissue-specific expression. Biochem J 1993;295:329-41.
28. Horikoshi Y, Sasaki A, Taguchi N et al. Human GLUT5 immu-nolabeling is useful for evaluating microglial status in neuro-pathological study using paraffin sections. Acta Neuropathol 2003;105:157-62.
29. Joost HG, Thorens B. The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members (review). Mol Membr Biol 2001;18:247-56.
30. Kayano T, Burant CF, Fukumoto H et al. Human facilitative glucose transporters. Isolation, functional characterization, and gene localization of cDNAs encoding an isoform (GLUT5) expressed in small intestine, kidney, muscle, and adipose tissue and an unusual glucose transporter pseudogene-like sequence (GLUT6). J Biol Chem 1990;265:13276-82.
31. Mayhan WG. Cellular mechanisms by which tumor necrosis factor-alpha produces disruption of the blood-brain barrier. Brain Res 2002;927:144-52.
32. Sasaki A, Horikoshi Y, Yokoo H et al. Antiserum against human glucose transporter 5 is highly specific for microglia among cells of the mononuclear phagocyte system. Neurosci Lett 2003;338:17-20.
33. Lu DY, Tang CH, Yeh WL et al. SDF-1alpha up-regulates interleukin-6 through CXCR4, PI3 K/Akt, ERK, and NF-kappaB-dependent pathway in microglia. Eur J Pharmacol 2009;613:146-54.
34. Cruz-Orengo L, Holman DW, Dorsey D et al. CXCR7 influences leukocyte entry into the CNS parenchyma by controlling abluminal CXCL12 abundance during autoimmunity. J Exp Med 2011;208:327-39.
35. Hill WD, Hess DC, Martin-Studdard A et al. SDF-1 (CXCL12) is upregulated in the ischemic penumbra following stroke: association with bone marrow cell homing to injury. J Neuropathol Exp Neurol 2004;63:84-96.
36. Huang J, Li Y, Tang Y et al. CXCR4 antagonist AMD3100 protects blood-brain barrier integrity and reduces inflammatory response after focal ischemia in mice. Stroke 2013;44:190-7.